Literature DB >> 6297637

Role of myeloperoxidase in the respiratory burst of human neutrophils.

W M Nauseef, J A Metcalf, R K Root.   

Abstract

Myeloperoxidase (MPO), a heme enzyme present in the primary granules of polymorphonuclear leukocytes (PMNs), has been demonstrated to participate in the oxygen-dependent microbicidal activity of these cells. Evidence for the importance of MPO in this role comes in part from studies of normal PMNs treated with the heme enzyme inhibitor, sodium azide. MPO has also been suggested to regulate the respiratory activity of PMNs during phagocytosis. The role of MPO in PMN oxygen metabolism was examined by studying parameters of the respiratory burst of PMNs from a number of unrelated MPO-deficient subjects; in addition, the ability of heme enzyme inhibitors to duplicate the MPO-deficient state was studied by treating normal and MPO-deficient cells with these compounds. MPO-deficient PMNs were found to have a time-dependent hypermetabolic response as assessed by measurement of oxygen consumption, superoxide generation, hydrogen peroxide release, and hexose monophosphate shunt activity. Catabolic pathways for hydrogen peroxide were normal, suggesting the increased recovery of oxygen metabolites reflects increased production rather than decreased catabolism of H2O2. These observations support the concept that MPO may play an important role in terminating the respiratory burst of normal PMNs. The three heme enzyme inhibitors studied--sodium azide, potassium cyanide, and 3-aminotriazole--differed greatly in the degree to which they inhibited various enzymatic systems in the PMN. Nonetheless, as a group, they exerted qualitatively similar effects on oxygen metabolism of normal and of MPO-deficient PMNs. This indicates that many of the mechanisms by which heme enzyme inhibitors influence PMN metabolism are independent of the inhibition of MPO. Conclusions from studies using such treatment of PMNs should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6297637

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  The proper study of mankind.

Authors:  W M Nauseef
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 2.  Assembly of the phagocyte NADPH oxidase.

Authors:  William M Nauseef
Journal:  Histochem Cell Biol       Date:  2004-08-04       Impact factor: 4.304

3.  Neutrophil-mediated cytotoxicity triggered by immune complexes: the role of reactive oxygen metabolites.

Authors:  J R Geffner; M Giordano; M S Palermo; A Prat; G P Serebrinsky; M A Isturiz
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

4.  The effects of high-intensity exercise on skeletal muscle neutrophil myeloperoxidase in untrained and trained rats.

Authors:  Vladimir I Morozov; Pavel V Tsyplenkov; Natalia D Golberg; Michael I Kalinski
Journal:  Eur J Appl Physiol       Date:  2006-06-22       Impact factor: 3.078

Review 5.  Nox enzymes in immune cells.

Authors:  William M Nauseef
Journal:  Semin Immunopathol       Date:  2008-05-01       Impact factor: 9.623

6.  Neutrophil degranulation inhibits potential hydroxyl-radical formation. Relative impact of myeloperoxidase and lactoferrin release on hydroxyl-radical production by iron-supplemented neutrophils assessed by spin-trapping techniques.

Authors:  B E Britigan; D J Hassett; G M Rosen; D R Hamill; M S Cohen
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

7.  Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease.

Authors:  Marla J Steinbeck; Leon J Nesti; Peter F Sharkey; Javad Parvizi
Journal:  J Orthop Res       Date:  2007-09       Impact factor: 3.494

8.  Adenosine and 2-phenylaminoadenosine (CV-1808) inhibit human neutrophil bactericidal function.

Authors:  G E Hardart; G W Sullivan; H T Carper; G L Mandell
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Myeloperoxidase modulates the phagocytic activity of polymorphonuclear neutrophil leukocytes. Studies with cells from a myeloperoxidase-deficient patient.

Authors:  O Stendahl; B I Coble; C Dahlgren; J Hed; L Molin
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

Review 10.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.